Connect with us

Headlines

Eye Health Firm Raises $15M for Alzheimer’s Test

mm

Published

on

Investors include J&J and VSP Global.

SACRAMENTO, CA — NeuroVision Imaging Inc. has announced a financing round of $15 million.

The Series C round, with an initial close of $11.2 million, was led by Wildcat Capital Management with funding from several new investment groups.

The financing provides support for NeuroVision as it seeks validation and regulatory approval for a noninvasive eye imaging system for measuring retinal autofluorescence that can detect amyloid beta plaque in the eye. Amyloid beta plaque deposits in the brain are a hallmark sign of Alzheimer’s disease, and histological evidence shows that amyloid beta plaque also accumulates in the retina, the photoreceptor and nerve complex at the rear of the eye, the company stated in a press release.

In addition to Wildcat Capital Management, participants in the round are Johnson & Johnson Innovation – JJDC Inc. (JJDC), Nikon-SBI Innovation Fund, Whittier Ventures LLC and VSP Global.

Advertisement

“We’re very pleased to announce this new round of financing and the confidence it represents from organizations dedicated to the development of innovative health care tools and solutions,” said Steven Verdooner, NeuroVision CEO. “Each participant in this round represents potential future strategic opportunities for the company as we move toward commercialization.”

Joining the funding round is VSP Global, which provides access to eye care for 88 million members through a network of 39,000 eye doctors worldwide. Eyefinity, as part of VSP Global, serves optometrists and the eye care community with the industry’s leading suite of practice management software and electronic health records solutions.

“NeuroVision’s groundbreaking technology provides for the important possibility of detecting neurodegenerative diseases earlier through the discovery of symptoms in the eyes,” said Steve Baker, president of Eyefinity. “In the end, this is about leading to better health outcomes and more coordinated patient care. We believe NeuroVision’s technology represents a great opportunity for optometry, underscoring the critical role the eye doctor plays within an increasingly integrated healthcare system. We are proud to support and work with NeuroVision in the eye care industry.”

Advertisement

SPONSORED VIDEO

SPONSORED BY VARILUX

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular